<DOC>
	<DOCNO>NCT02783092</DOCNO>
	<brief_summary>The purpose study assess efficacy adjuvant use cannabidiol administer twice daily dos 5-25 mg/kg/day proportion responsive patient ; , participant least 50 % decrease frequency epileptic seizure last month trial relative baseline ( pretreatment AEDs ) . Primary end point ( ) : Rate responsive patient ; , participant least 50 % decrease frequency epileptic seizure last month trial relative baseline ( pretreatment AEDs ) .</brief_summary>
	<brief_title>A Double Blind , Randomized Placebo-controlled Trial Evaluate Efficacy Safety Cannabidiol add-on Therapy Treatment Refractory Epileptic Crisis Children Adolescents</brief_title>
	<detailed_description />
	<criteria>Men woman age 6 month 18 year . Diagnosis treatmentresistant epilepsy accord criterion International League Against Epilepsy ( ILAE ) ( Kwan et al. , 2010 ) . Participants least 4 epileptic seizure interval longer 21 day . In treatment 3 AEDs concomitantly stable dos least 1 month baseline assessment expect remain stable period trial . Vagus nerve stimulation ( VNS ) consider AED . Availability legal guardian able follow protocol ( e.g. , understand fill diary ) visitation medication scheme , accord decision investigator . Availability brain neuroimaging exam ( magnetic resonance compute tomography ) collect within last 5 year . No significant comorbid condition , accord medical decision , criterion Protocol , additional assessment : medical record , blood pressure , heart rate , temperature measure , physical exam , ECG , EEG , laboratory test . Women reproductive age may include long sexually abstinent use effective contraceptive method . Participants legal guardian , applicable , must sign informed consent form approve local ethic committee . Occurrence simple partial seizure ( preserved consciousness ) , motor symptomatology . History presence pseudoseizures . History suicide attempt . History major depression . Pregnancy . Drug use . Hypertension . Participants severe dysphagia gastric nasogastric tube . Current treatment drug may significantly affect metabolism CBD , except AEDs stable least 1 month screen interview . Presence clinical neuroimaging find suggestive brain disorder , brain tumor , metabolic neurodegenerative disease rapid progression . Presence acute clinically significant disease assess medical investigator , kidney , liver , urinary , bowel , respiratory infection . Presence know chronic clinically significant disease assess medical investigator may interfere participation trial pose safety risk participant . History liver , kidney , lung , hematological , heart , psychiatric disease may affect volunteer ' health participation trial . Hypotension hypertension etiology require pharmacological management . History surgery may affect volunteer ' health and/or participation trial . Regular intermittent use marijuana 60 day precede baseline assessment . Regular intermittent treatment CBD 60 day precede baseline assessment . History allergies idiosyncratic reaction Cannabis sativa derivative component pharmaceutical formulation . Clinically significant ECG alteration judge medical investigator . Participation clinical trial within less 3 month baseline assessment . Donation loss 450 mL blood within 90 day baseline assessment . Impaired liver function : AST , ALP , alkaline phosphatase γGT value 3 time upper limit reference value . Results γGT value 3 time upper limit accept attributable liver enzymatic induction cause concomitant treatment AEDs level liver enzymes low 3 time upper limit reference range . Participants clinically significant discrepancy reference range follow laboratory test : creatinine clearance &lt; 50 ml/min , platelet &lt; 100.000/μL , neutrophil &lt; 1.800/μL .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>